What it is
Caspofungin was the first echinocandin antifungal the FDA approved. The US label calls it "a semisynthetic lipopeptide (echinocandin) compound synthesized from a fermentation product of Glarea lozoyensis." It was the first of the four echinocandins approved in the United States, on 26 January 2001 as Merck's Cancidas.
Like the rest of its class, it is a peptide only in a chemist's sense. The label's chemical name describes a modified pneumocandin B0 — a natural product of the fungus — carrying modified ornithines in place of ordinary amino acids. Caspofungin acetate's empirical formula is C52H88N10O15·2C2H4O2, formula weight 1,213.42.
How it works
The label gives the mechanism in its microbiology section: caspofungin inhibits the synthesis of beta (1,3)-D-glucan, "an essential component of the cell wall of susceptible Aspergillus species and Candida species," and that polymer "is not present in mammalian cells."
Resistance is recorded there too: treatment failures have been traced to changes in the enzyme's Fks subunits, coded by the fks1 and fks2 genes, which raise the concentration needed to inhibit the fungus.
What the label's trials show
| Use (label) | Trial design | Result |
|---|---|---|
| Fever with very low neutrophils (empirical) | Double-blind, 1,111 patients, vs AmBisome 3 mg/kg/day | Overall favourable response 190/556 (33.9%) vs 181/539 (33.7%); difference 0.2, 95.2% CI −5.6 to 6.0 |
| Candidemia and other invasive Candida | Randomised, double-blind, 239 enrolled, vs amphotericin B deoxycholate | Favourable at end of IV therapy 81/109 (74.3%) vs 78/115 (67.8%); 7.5, CI −5.4 to 20.3 |
| Oesophageal candidiasis | Randomised, double-blind, non-inferiority, vs IV fluconazole 200 mg/day | Favourable 66/81 (81.5%) vs 80/94 (85.1%); −3.6, 95% CI −14.7 to 7.5 |
| Invasive aspergillosis after other drugs | Open-label, no comparator, 69 enrolled, 63 evaluable | Favourable response 26/63 (41%); 26/52 (50%) if treated more than 7 days |
What the table does and does not show, in the label's own terms. In the first three trials the confidence intervals cross zero, so they support similar performance to the comparator, not superiority. The aspergillosis result has no control arm: among patients refractory to earlier drugs the favourable rate was 19 of 53 (36%), among those intolerant of them 7 of 10 (70%).
The label also records a relapse signal in the oesophageal trial. At day 28 after treatment, 18 of 64 (28.1%) on caspofungin had relapsed against 12 of 72 (16.7%) on fluconazole — a difference the label describes as not statistically significant. In the patients who also had candidiasis of the mouth and throat, day-14 relapse was 17/40 (42.5%) vs 7/53 (13.2%). The label adds that caspofungin "has not been approved for the treatment of oropharyngeal candidiasis."
Doses on the label
These are the label's figures, reported as published; a patient's dose is decided by the clinicians treating them.
| Group (label) | Dose |
|---|---|
| Adults, most indications | 70 mg loading dose on day 1, then 50 mg once daily |
| Adults, oesophageal candidiasis | 50 mg once daily, no loading dose |
| Adults, moderate liver impairment | 35 mg once daily (with a 70 mg loading dose where appropriate) |
| Children 3 months to 17 years | 70 mg/m² on day 1, then 50 mg/m² daily; never above 70 mg |
The label raises the daily dose to 70 mg in adults taking rifampin and says an increase may be considered with nevirapine, efavirenz, carbamazepine, dexamethasone or phenytoin. Every dose is a slow intravenous infusion over about an hour.
In the body
The label describes plasma levels falling in phases: a short early phase, a main phase with a half-life of 9 to 11 hours, and a longer phase of 40 to 50 hours. About 97% is bound to albumin, and distribution into tissues rather than excretion drives the early fall — about 92% of a radiolabelled dose had moved into tissues by 36–48 hours. The molecule also breaks open on its own in the body, forming an open-ring peptide the label names L-747969.
Safety
The label's warnings are hypersensitivity — anaphylaxis, possible histamine-type reactions, and cases of Stevens-Johnson syndrome and toxic epidermal necrolysis, some fatal — and liver effects, from enzyme rises to isolated cases of hepatitis and liver failure. A separate warning covers raised liver enzymes with cyclosporine.
The most common adverse reactions in adults (10% or more) were diarrhoea, fever, raised liver enzymes, raised alkaline phosphatase and low potassium. No long-term animal studies of cancer risk have been performed, the label states; its genetic-toxicity tests were negative.
Where it stands
- Approved in the US since 2001-01-26 (Cancidas, Merck, NDA 021227).
- Brand: Drugs@FDA lists that application as discontinued (read 2026-11-12). Merck's label in the FDA label database carries an effective date of 2024-10-11.
- Other products: Fresenius Kabi's application (NDA 206110) and generics from Gland, Areva and Hangzhou Zhongmei are listed as prescription products; four further generic applications are discontinued.
- Research record: PubMed indexes 4,225 records, 55 tagged as randomised controlled trials; ClinicalTrials.gov returns 99 records (2026-11-12).
Related reading
The four approved members of the class are set side by side in the echinocandins entry, and the closest single comparison is micafungin, which beat caspofungin's success rate numerically but not decisively in its own label trial. The same ring-plus-fatty-tail design turns up in the bacterial-membrane antibiotic daptomycin and in surfactin, a soil-bacterium lipopeptide. For a contrast with an antibiotic that attacks a peptide-crosslinked wall rather than a sugar one, see the peptidoglycan entry.
Caspofungin was also the comparator in the trial behind the once-weekly echinocandin: the library's rezafungin entry gives that trial's results.
